Global Joint Pain Injections Market Size study & Forecast, by Injection Type (Interleukin Inhibitors, Hyaluronic Acid Injections), by Joint Type (Knee and Ankle, Hip Joint, Shoulder and Elbow, Facet Joints of the Spine), by Distribution Channel (Hospital

Global Joint Pain Injections Market Size study & Forecast, by Injection Type (Interleukin Inhibitors, Hyaluronic Acid Injections), by Joint Type (Knee and Ankle, Hip Joint, Shoulder and Elbow, Facet Joints of the Spine), by Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) and Regional Analysis, 2022-2029

Global Joint Pain Injections Market is valued approximately USD 6.3 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 7.7% over the forecast period 2022-2029. Arthritis injections are given directly into the joints to relieve pain and minimize inflammation and swelling. Joint pain usually occurs in the elderly as a result of pre-existing diseases or conditions. Arthritis is a common disease that mainly occurs in the knee, ankle, hip, shoulder, elbow, and facet joints of the spine, causing joint pain that causes inflammation and increases joint discomfort. The increasing prevalence of osteoarthritis and rheumatoid arthritis and growing need for affordable treatment solutions as well as rising rate of injuries due to accidents are key factors accelerating the market growth.

The rising prevalence of osteoarthritis and rheumatoid arthritis is contributing to the growth of the Global Joint Pain Injections Market. For instance, according to The Arthritis Foundation estimates – as of 2019, approximately more than 91 million adults in the U.S. living with arthritis, and the number is protected to reach to 113 million by 2040. Additionally, the number of adults in the U.S. with doctor-diagnosed arthritis is likely to increase to 78.4 million, and the number of individuals reporting activity limitations due to arthritis would increase to 34.6 million by 2040. Also, rising number of geriatric individuals and growing healthcare infrastructure in developing regions would create lucrative growth prospectus for the market over the forecast period. However, stringent regulatory framework for treatment approval stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Joint Pain Injections Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of leading market players and increasing prevalence of arthritis in the region. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and rising expansion of contract manufacturing organizations, coupled with increasing penetration of leading market players in the region.

Major market player included in this report are:
Abbvie Inc.
Anika Therapeutics
Bioventus
Eli Lilly and Company
Ferring Pharmaceuticals Inc.
PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)
Pfizer Inc.
Sanofi S.A.
Teva Pharmaceuticals
Zimmer Biomet
Recent Developments in the Market:
 In July 2019- Tel Aviv, Israel based Teva Pharmaceutical Industries Ltd. has launched 1% Sodium Hyaluronate in the U.S. market after receiving approval from the Center for Devices and Radiological Health of the U.S. FDA. This new product is intended for the treatment of pain associated with osteoarthritis in the knee

Global Joint Pain Injections Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Injection Type, Joint Type, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Injection Type
Interleukin Inhibitors
Hyaluronic Acid Injections
By Joint Type
Knee and Ankle
Hip Joint
Shoulder and Elbow
Facet Joints of the Spine
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Abbvie Inc.
Anika Therapeutics
Bioventus
Eli Lilly and Company
Ferring Pharmaceuticals Inc.
PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)
Pfizer Inc.
Sanofi S.A.
Teva Pharmaceuticals
Zimmer Biomet

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions